Solutions Ecosystems Reports Resources Data Pricing Login Book a demo
Power Law company profile

Orchard Therapeutics

Biotech & Life Sciences · London, United Kingdom · Founded 2015 · IPO 2018 Unicorn

Hematopoietic stem cell gene therapies for rare diseases

Valuation
$303M
Market cap · 2026
Revenue
$20M
Latest reported FY

Investors

20 investors on Orchard Therapeutics's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 1 investor entered at this stage
Series B+ 19 investors entered at this stage
Venrock
4BIO Capital
ArrowMark Partners
Temasek
ORI Capital
Cormorant Asset Management
Baillie Gifford
Perceptive Advisors
Cowen Group
RTW Investments
AlbionVC
UCL Technology Fund
Agent Capital
RA Capital Management
Pavilion Capital Partners
Deerfield
Juda Capital
Foresite Capital
University College London

Global footprint

Where Orchard Therapeutics has talent and traffic

AI talent share
0.4% of workforce is AI talent
(1 of 239 staff)
Core AI00%
Other AI10.42%
Non-AI workforce23899.58%
Workforce by country
11 countries with
team presence
🇬🇧 United Kingdom60.9%
🇺🇸 United States22.8%
🇫🇷 France4.3%
🇨🇭 Switzerland3%
🇮🇹 Italy2.8%
Top 5 of 11 shown
Web traffic by country
11K monthly visits
across markets
🇺🇸 United States69.1%
🇬🇧 United Kingdom11.8%
🇮🇳 India7.3%
🇫🇷 France6.4%
🇵🇭 Philippines1.8%
Top 5 markets shown

Market sentiment

What the market is saying about Orchard Therapeutics

An AI-synthesized read of the highest-engagement posts about Orchard Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Orchard Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.